Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia. (2018)

Peer-Reviewed Study · Licai He; Liuzhi Shi; Zhuanyun Du et al. · August 1, 2018

Licai He et al., 2018-08-01: He et al. screened over 1,000 FDA-approved drugs and found mebendazole inhibits AML lines and patient marrow mononuclear cells at achievable concentrations, with xenograft survival benefit.

Finally, MBZ repressed the progression of leukemic cells in vivo and prolonged survival in AML xenograft mouse model.

Licai He et al., 2018-08-01: He et al. screened over 1,000 FDA-approved drugs and found mebendazole inhibits AML lines and patient marrow mononuclear cells at achievable concentrations, with xenograft survival benefit. Study type: AML cell lines, patient bone marrow mononuclear cells, and AML xenograft mice. N: not stated in the abstract. Country: China (Wenzhou Medical University). Dose: 'pharmacologically achievable concentrations', values not stated in the abstract. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: normal PBMC and HUVEC for toxicity, and untreated xenografts. Study type: animal.